Can we tell which prostate cancers are dangerous? new study aims to find out.
NCT ID NCT00756665
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 3,000 men with early-stage prostate cancer who have chosen active surveillance (close monitoring instead of immediate treatment). The goal is to discover biological markers that can tell apart aggressive cancers from slow-growing ones. Researchers hope this will help men avoid unnecessary treatments while catching dangerous cancers early.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center/Harvard Medical School
RECRUITINGBoston, Massachusetts, 02215, United States
-
Eastern Virginia Medical School
RECRUITINGNorfolk, Virginia, 23502, United States
-
Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
-
Stanford University
RECRUITINGStanford, California, 94305, United States
-
University of British Columbia
RECRUITINGVancouver, British Columbia, V5Z 1M9, Canada
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48105, United States
-
University of Texas Health Science Center, San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
-
University of Washington
RECRUITINGSeattle, Washington, 98195, United States
-
Veterans Affairs Puget Sound Health Care System
RECRUITINGSeattle, Washington, 98108, United States
-
Veterans Affairs San Francisco Health Care System
RECRUITINGSan Francisco, California, 94121, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug deliver a toxic payload to prostate cancer cells?
- Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards
- Hormone therapy showdown: can an oral pill beat the shot for prostate cancer patients?
- Can a new daily pill slow advanced prostate cancer?
- Immunotherapy combo takes on Hard-to-Treat prostate cancer
- Could a targeted drug delay prostate cancer progression?